Chardan Capital Brokers Decrease Earnings Estimates for LXEO

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Equities researchers at Chardan Capital decreased their FY2024 earnings per share estimates for Lexeo Therapeutics in a note issued to investors on Wednesday, November 13th. Chardan Capital analyst G. Livshits now expects that the company will post earnings per share of ($3.03) for the year, down from their prior forecast of ($2.93). Chardan Capital has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.05) per share. Chardan Capital also issued estimates for Lexeo Therapeutics’ FY2025 earnings at ($2.30) EPS.

Several other analysts have also issued reports on LXEO. Leerink Partners cut their target price on Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research note on Wednesday, November 13th. HC Wainwright boosted their price objective on shares of Lexeo Therapeutics from $21.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, November 14th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $24.00 target price on shares of Lexeo Therapeutics in a report on Tuesday, August 13th. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $22.71.

Lexeo Therapeutics Price Performance

LXEO opened at $6.00 on Monday. The stock has a market capitalization of $198.40 million and a P/E ratio of -1.93. The company has a current ratio of 5.95, a quick ratio of 9.38 and a debt-to-equity ratio of 0.01. Lexeo Therapeutics has a 12-month low of $5.81 and a 12-month high of $22.33. The stock has a 50-day moving average price of $9.01 and a 200-day moving average price of $12.23.

Insider Buying and Selling at Lexeo Therapeutics

In other news, CEO Richard Nolan Townsend sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 10th. The shares were sold at an average price of $8.10, for a total value of $40,500.00. Following the transaction, the chief executive officer now owns 120,695 shares in the company, valued at approximately $977,629.50. This trade represents a 3.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last 90 days, insiders sold 12,500 shares of company stock worth $113,300. 4.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Lexeo Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets purchased a new position in Lexeo Therapeutics during the 1st quarter valued at about $75,000. Vanguard Group Inc. increased its stake in shares of Lexeo Therapeutics by 15.8% during the first quarter. Vanguard Group Inc. now owns 481,755 shares of the company’s stock valued at $7,554,000 after buying an additional 65,573 shares during the period. American International Group Inc. bought a new position in shares of Lexeo Therapeutics during the first quarter valued at approximately $79,000. Janus Henderson Group PLC raised its holdings in shares of Lexeo Therapeutics by 9.0% during the first quarter. Janus Henderson Group PLC now owns 2,540,785 shares of the company’s stock valued at $39,802,000 after acquiring an additional 210,047 shares in the last quarter. Finally, Artal Group S.A. lifted its stake in Lexeo Therapeutics by 32.9% in the first quarter. Artal Group S.A. now owns 801,716 shares of the company’s stock worth $12,571,000 after acquiring an additional 198,281 shares during the period. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.